Xoma Spinout Readies NDA For Hypertension Combination Product
This article was originally published in The Pink Sheet Daily
New company Symplmed takes over Xoma’s perindopril partnership with Servier, readying a combination product with amlodipine for U.S. approval in hypertension, while holding options on two other fixed-dose combinations including the ACE inhibitor.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.